We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

24 hedge funds and large institutions have $61.7M invested in Sinovac Biotech, Ltd in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more capital invested

Capital invested by funds: $23.9M → $61.7M (+$37.8M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

4% less funds holding

Funds holding: 25 → 24 (-1)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
24
Holders Change
-1
Holders Change %
-4%
% of All Funds
0.53%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
3
Increased
1
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$38.2M
2
JP Morgan Chase
JP Morgan Chase
New York
+$3K

Top Sellers

Rank Fund Capital Flow
1
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$202K
2
TRCT
Tower Research Capital (TRC)
New York
-$3K
3
FIM
Freedom Investment Management
Connecticut
-$45
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$38.2M +$38.2M +5,900,000 New
O
2
OrbiMed
New York
$17.2M – – –
NAH
3
Neumann Advisory (HK)
Hong Kong
$2.04M – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$1.54M – – –
State Street
5
State Street
Massachusetts
$1.04M – – –
YMRC
6
Yorktown Management & Research Company
Virginia
$485K – – –
California Public Employees Retirement System
7
California Public Employees Retirement System
California
$445K – – –
Skandinaviska Enskilda Banken (SEB)
8
Skandinaviska Enskilda Banken (SEB)
Sweden
$259K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$179K – – –
FIM
10
Freedom Investment Management
Connecticut
$134K -$45 -7 -0%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$106K – – –
Northern Trust
12
Northern Trust
Illinois
$55K – – –
UBS Group
13
UBS Group
Switzerland
$55K – – –
Morgan Stanley
14
Morgan Stanley
New York
$9K – – –
Group One Trading
15
Group One Trading
Illinois
$3K – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$3K +$3K +400 New
FGAM
17
Financial Gravity Asset Management
Texas
$1.18K – – –
CIBC Private Wealth Group
18
CIBC Private Wealth Group
Georgia
– -$202K -24,600 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$3K -424 Closed

SVA Hedge Fund Activity: Q1 2020 in Review

24 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2020, worth a combined $61.7M — up 158% from $23.9M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SVA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $38.2M. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $202K sold.

  • 24 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2020, down from 25 in Q4 2019.
  • Funds reported $61.7M of Sinovac Biotech, Ltd stock for Q1 2020, up 158% quarter-over-quarter.
  • 3 funds opened new Sinovac Biotech, Ltd positions in Q1 2020 and 2 closed out, a net change of +1 holder.
  • The largest Sinovac Biotech, Ltd buyer in Q1 2020 was Vivo Capital, an estimated $38.2M added.
  • The largest Sinovac Biotech, Ltd seller in Q1 2020 was CIBC Private Wealth Group, an estimated $202K sold.

Based on aggregated 13F filings for Q1 2020.